Description

Disclaimer: This is a research chemical only. It’s not a medication, and it’s not approved for human or animal use outside of authorized studies

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone–releasing hormone (GHRH) designed to provide prolonged biological activity compared to its non-DAC counterpart. The inclusion of DAC enables the peptide to bind to serum albumin, dramatically extending its half-life from minutes to days, which allows for sustained stimulation of growth hormone (GH) secretion in experimental systems.

Researchers frequently study CJC-1295 with DAC in the context of long-term GH modulation, examining how extended pulsatile release influences tissue growth, repair mechanisms, and metabolic regulation. Its extended duration allows for fewer administrations in chronic investigative models, providing distinct advantages in controlled studies that simulate persistent GH exposure over weeks rather than hours.

Scientific investigations often focus on the peptide’s ability to upregulate GH and subsequently elevate insulin-like growth factor 1 (IGF-1) levels, thereby offering insights into anabolic processes, protein synthesis, and recovery pathways. Studies also examine how CJC-1295 with DAC affects adipose tissue metabolism, glucose regulation, and endocrine system feedback loops, making it a valuable model compound for exploring metabolic disease mechanisms.

Beyond metabolic research, CJC-1295 with DAC is investigated for its potential roles in musculoskeletal recovery, connective tissue repair, and age-related decline of endogenous GH production. By maintaining elevated baseline GH signaling in laboratory settings, it enables exploration of regenerative pathways that are difficult to sustain with shorter-acting analogs.

Overall, CJC-1295 with DAC serves as a critical tool for researchers seeking to model long-term GH regulation, test chronic dosing paradigms, and study endocrine and regenerative pathways under extended stimulation conditions.